TY - JOUR T1 - Elucidation of the Binding Mode of the Carboxyterminal Region of Peptide YY to the Human Y<sub>2</sub> Receptor JF - Molecular Pharmacology JO - Mol Pharmacol SP - 323 LP - 334 DO - 10.1124/mol.117.110627 VL - 93 IS - 4 AU - Bo Xu AU - Silvana Vasile AU - Søren Østergaard AU - Johan F. Paulsson AU - Jasna Pruner AU - Johan Åqvist AU - Birgitte S. Wulff AU - Hugo Gutiérrez-de-Terán AU - Dan Larhammar Y1 - 2018/04/01 UR - http://molpharm.aspetjournals.org/content/93/4/323.abstract N2 - Understanding the agonist-receptor interactions in the neuropeptide Y (NPY)/peptide YY (PYY) signaling system is fundamental for the design of novel modulators of appetite regulation. We report here the results of a multidisciplinary approach to elucidate the binding mode of the native peptide agonist PYY to the human Y2 receptor, based on computational modeling, peptide chemistry and in vitro pharmacological analyses. The preserved binding orientation proposed for full-length PYY and five analogs, truncated at the amino terminus, explains our pharmacological results where truncations of the N-terminal proline helix showed little effect on peptide affinity. This was followed by receptor mutagenesis to investigate the roles of several receptor positions suggested by the modeling. As a complement, PYY-(3-36) analogs were synthesized with modifications at different positions in the common PYY/NPY C-terminal fragment (32TRQRY36-amide). The results were assessed and interpreted by molecular dynamics and Free Energy Perturbation (FEP) simulations of selected mutants, providing a detailed map of the interactions of the PYY/NPY C-terminal fragment with the transmembrane cavity of the Y2 receptor. The amidated C-terminus would be stabilized by polar interactions with Gln2886.55 and Tyr2195.39, while Gln1303.32 contributes to interactions with Q34 in the peptide and T32 is close to the tip of TM7 in the receptor. This leaves the core, α-helix of the peptide exposed to make potential interactions with the extracellular loops. This model agrees with most experimental data available for the Y2 system and can be used as a basis for optimization of Y2 receptor agonists. ER -